Shares of ResMed Inc. (NYSE:RMD) have been assigned a consensus rating of “Hold” from the twelve analysts that are currently covering the company, MarketBeat reports. Four investment analysts have rated the stock with a sell recommendation, four have issued a hold recommendation, three have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $65.00.

Several equities research analysts recently commented on the stock. Zacks Investment Research upgraded shares of ResMed from a “hold” rating to a “buy” rating and set a $87.00 price target for the company in a research report on Thursday, July 6th. BidaskClub upgraded shares of ResMed from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 17th. Jefferies Group LLC reiterated a “sell” rating and issued a $56.00 price objective on shares of ResMed in a research note on Friday, April 28th. Citigroup Inc. lowered shares of ResMed from a “buy” rating to a “neutral” rating in a research note on Friday, April 28th. Finally, BMO Capital Markets restated a “hold” rating on shares of ResMed in a research note on Friday, May 12th.

ResMed (NYSE RMD) traded up 0.25% during midday trading on Monday, hitting $77.19. 1,065,487 shares of the stock were exchanged. The firm’s 50-day moving average is $76.25 and its 200 day moving average is $70.99. ResMed has a 52 week low of $56.59 and a 52 week high of $79.44. The stock has a market cap of $10.95 billion, a price-to-earnings ratio of 33.86 and a beta of 0.84.

ResMed (NYSE:RMD) last released its earnings results on Thursday, April 27th. The medical equipment provider reported $0.71 EPS for the quarter, beating the consensus estimate of $0.70 by $0.01. ResMed had a net margin of 15.96% and a return on equity of 22.53%. The business had revenue of $514.20 million during the quarter, compared to analyst estimates of $525.84 million. During the same period in the prior year, the business earned $0.68 earnings per share. The business’s quarterly revenue was up 13.3% on a year-over-year basis. Equities research analysts expect that ResMed will post $2.80 EPS for the current fiscal year.

In other ResMed news, CFO Brett Sandercock sold 1,250 shares of the firm’s stock in a transaction dated Monday, May 1st. The shares were sold at an average price of $68.60, for a total value of $85,750.00. Following the completion of the sale, the chief financial officer now owns 62,783 shares in the company, valued at approximately $4,306,913.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Richard Sulpizio sold 65,887 shares of the firm’s stock in a transaction dated Thursday, June 22nd. The shares were sold at an average price of $77.82, for a total transaction of $5,127,326.34. Following the completion of the sale, the director now owns 4,429 shares of the company’s stock, valued at approximately $344,664.78. The disclosure for this sale can be found here. Insiders have sold a total of 180,261 shares of company stock valued at $13,560,373 in the last quarter. 1.97% of the stock is currently owned by corporate insiders.

A number of large investors have recently bought and sold shares of RMD. BlackRock Inc. boosted its stake in ResMed by 5,439.8% in the first quarter. BlackRock Inc. now owns 13,335,138 shares of the medical equipment provider’s stock valued at $959,731,000 after buying an additional 13,094,421 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of ResMed by 4.6% in the first quarter. Vanguard Group Inc. now owns 11,535,707 shares of the medical equipment provider’s stock valued at $830,225,000 after buying an additional 508,392 shares in the last quarter. State Street Corp boosted its stake in shares of ResMed by 2.1% in the first quarter. State Street Corp now owns 4,598,911 shares of the medical equipment provider’s stock valued at $330,983,000 after buying an additional 95,552 shares in the last quarter. FMR LLC boosted its stake in shares of ResMed by 1.9% in the first quarter. FMR LLC now owns 4,010,810 shares of the medical equipment provider’s stock valued at $288,659,000 after buying an additional 74,389 shares in the last quarter. Finally, Morgan Stanley boosted its stake in shares of ResMed by 69.1% in the first quarter. Morgan Stanley now owns 1,344,234 shares of the medical equipment provider’s stock valued at $96,744,000 after buying an additional 549,279 shares in the last quarter. Hedge funds and other institutional investors own 60.73% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another website, it was illegally copied and reposted in violation of United States and international trademark and copyright law. The legal version of this article can be read at https://www.americanbankingnews.com/2017/07/24/resmed-inc-nysermd-given-consensus-rating-of-hold-by-brokerages.html.

ResMed Company Profile

ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.

Analyst Recommendations for ResMed (NYSE:RMD)

Receive News & Ratings for ResMed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed Inc. and related companies with MarketBeat.com's FREE daily email newsletter.